Replies to post #10281 on Biotech Values

[DewDiligence]

>>…am i to understand that dndn submitted an abstract to asco, had it officially accepted, and then pulled the presentation?<<

You seem to be right. DNDN’s 9902a presentation by Dr. Higano is no longer listed on the prostate-cancer program at:

http://www.asco.org/ac/1,1003,_12-002556-00_18-008954,00.asp

In an earlier version of the ASCO schedule (#msg-6007293), Dr. Higano was on tap for an oral presentation during this session.

What gives?

[walldiver]

The clinical investigator Dr. Celestia Higano on 9902A submitted an abstract in December in order to make the deadline. She probably didn't know at the time that DNDN was planning on unblinding 9902A for the progression data. When DNDN announced the progression miss and the interim 9902A survival data in January, they asked ASCO to pull the presentation. ASCO did, but apparently failed to inform their webmaster. Within one day or so of seeing it show up on the website, it was pulled from the website. Apparently, after January, it never was on the official agenda.

Both Dr. Higano and DNDN have confirmed this, just not with a press release.